1Stein I,Leventhal M. Amenorrhoea associated with bilateral polycystic ovaries[J].American Journal of Obstetrics and Gynecology,1935.181-185.
2Azziz R,Woods KS,Reyna R. The prevalence and features of the polycystic ovary syndrome in an unselected population[J].Journal of Clinical Endocrinology and Metabolism,2004.2745-2749.
3Dunaif A. Insulin resistance in women with polycystic ovary syndrome[J].Fertility and Sterility,2006,(z 1):S13-S14.
5Deligeoroglou E,Kouskouti C,Christopoulos P. The role of genes in the polycystic ovary syndrome:predisposition and mechanisms[J].Gynecological Endocrinology,2009.1-7.
6Carmina E,Azziz R. Diagnosis,phenotype,and prevalence of polycystic ovary syndrome[J].Fertility and Sterility,2006,(z 1):S7-S8.doi:10.1016/j.fertnstert.2006.03.012.
7Azziz R,Carmina E,Dewailly D. Position statement:criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline[J].Journal of Clinical Endocrinology and Metabolism,2006.4237-4245.
8Galluzzo A,Amato MC,Giordano C. Insulin resistance and polycystic ovary syndrome[J].Nutrition Metabolism and Cardiovascular Diseases,2008.511-518.
10Matthews DR,Hosker JP,Rudenski AS. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man[J].Diabetologia,1985.412-419.
4Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and 13-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985,28:412- 419.
5Wallace RM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004,27 : 1487-1495.
6Lehto M, Tuomi T, Mahtani MM, et al. Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest, 1997,99:582-591.
7Tripathy D, Wessman Y, GullstromM, et al. Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test-results with the botnia clamp. Diabetes Care, 2003,26: 1395- 1401.
8Dunaif A,Finegood DT.Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.J Clin Endocrinol Metab,1996,81:942-947.
10Tripathy D,Wessman Y,Gullstrom M,et al.Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test:results with the Botnia clamp.Diabetes Care,2003,26:1395-1401.
2Nasreddine L,Naja F, Tabet M, et al. Obesity is associated with insulin resistance and components of the metabolic syndrome in Lebanese adolescents[J]. Ann Hum Bioi,2012,39 (2):122-128.
3Pasquali R, Gambineri A. Insulin sensitizers in polieystic ovary syndrome[J]. Front Horm Res,2013,40:83-102.
4Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Ferti Steril,2004,81(1):19-25.
6Astrup A, RSssner S, Van Gaal L, et al. Effects of Liraglutide in the treatment of obesity:a randomized,double- blind,placebo-controlled study[J]. Lancet,2009,374(9701): 1606-1616.
7Huang J, Ni R, Chen X, et al. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south china[J]. Reprod Biol Endocrinol,2010,8:142.
8Moran LJ, Miss ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta- analysis[J]. Hum Reprod Update,2010,16(4):347-363.
9Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements[J]. Diabetes Technol Tber,2011,13 (5):592-595.
10Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity [J]. Clin Med,2012, 12(5):456-460.
